Association between tight junction proteins and cognitive performance in untreated persons with HIV

Background: HIV-associated neurocognitive disorders (HAND) still affects persons with HIV (PWH) and their pathogenesis is not completely understood. We aimed to explore the association between plasma and cerebrospinal fluid (CSF) markers of blood–brain barrier (BBB) impairment and HAND in untreated PWH. Design: Cross-sectional study. Methods: We enrolled untreated PWH, who underwent blood examinations and lumbar puncture to measure inflammation (IL-15, TNF-α), BBB damage (zonulin and tight junction proteins, tight junction proteins: occludin, claudin-5) and endothelial adhesion molecules (VCAM-1, ICAM-1). A comprehensive neurocognitive battery was used to diagnose HAND (Frascati criteria). Results: Twenty-one patients (21/78, 26.9%) patients presented HAND (100% ANI). HAND patients displayed more frequently non-CNS AIDS-defining conditions, lower nadir CD4+ T cells and increased CD4+ T-cell exhaustion (lower CD4+CD127+ and CD4+CD45RA+ T-cell percentages), in comparison to individuals without cognitive impairment. Furthermore, HAND was characterized by higher plasma inflammation (IL-15) but lower CSF levels of biomarkers of BBB impairment (zonulin and occludin). The association between BBB damage with HAND was confirmed by fitting a multivariable logistic regression. CSF/plasma endothelial adhesion molecules were not associated with HAND but with a poor performance in different cognitive domains. Conclusion: By showing heightened inflammation and BBB impairment, our study suggests loss of BBB integrity as a possible factor contributing to the development of HAND in untreated PWH.

[1]  H. Uno,et al.  Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy , 2023, medRxiv : the preprint server for health sciences.

[2]  C. Cervellati,et al.  Serum zonulin levels are increased in Alzheimer’s disease but not in vascular dementia , 2023, Aging Clinical and Experimental Research.

[3]  B. Ances,et al.  Cognitive impairment in people living with HIV: consensus recommendations for a new approach , 2023, Nature Reviews Neurology.

[4]  J. Routy,et al.  Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV , 2023, Frontiers in Immunology.

[5]  C. Scagnolari,et al.  The crosstalk between gut barrier impairment, mitochondrial dysfunction, and microbiota alterations in people living with HIV , 2022, Journal of medical virology.

[6]  R. Paredes,et al.  Determinants of HIV-1 Late Presentation in Patients Followed in Europe , 2021, Pathogens.

[7]  G. C. Souza,et al.  Could serum zonulin be an intestinal permeability marker in diabetes kidney disease? , 2021, PloS one.

[8]  Sube Banerjee,et al.  Quality of life in people living with HIV-associated neurocognitive disorder: A scoping review study , 2021, PloS one.

[9]  C. Andrés-Lacueva,et al.  A polyphenol-rich dietary pattern improves intestinal permeability, evaluated as serum zonulin levels, in older subjects: The MaPLE randomised controlled trial. , 2020, Clinical nutrition.

[10]  A. Lasek-Bal,et al.  Plasma Levels of Occludin and Claudin-5 in Acute Stroke Are Correlated with the Type and Location of Stroke but Not with the Neurological State of Patients—Preliminary Data , 2020, Brain sciences.

[11]  K. Blennow,et al.  Cognitive and neuronal link with inflammation: a longitudinal study in people with and without HIV infection. , 2020, Journal of acquired immune deficiency syndromes.

[12]  K. Überla,et al.  Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis , 2020, Nature Communications.

[13]  A. Sporbert,et al.  Tight junction proteins at the blood–brain barrier: far more than claudin-5 , 2019, Cellular and Molecular Life Sciences.

[14]  P. Galanis,et al.  Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review , 2019, Therapeutic advances in infectious disease.

[15]  Berislav V. Zlokovic,et al.  Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.

[16]  L. Cysique,et al.  HIV-Associated Neurocognitive Disorders: A Global Perspective , 2017, Journal of the International Neuropsychological Society.

[17]  X. Jiao,et al.  Circulating tight junction proteins mirror blood–brain barrier integrity in leukaemia central nervous system metastasis , 2017, Hematological oncology.

[18]  N. Sacktor.  Changing clinical phenotypes of HIV-associated neurocognitive disorders , 2017, Journal of NeuroVirology.

[19]  Mark Obermann,et al.  HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment , 2017, Journal of Neurology.

[20]  D. Fuchs,et al.  Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy , 2017, The Journal of infectious diseases.

[21]  F. Bai,et al.  Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients , 2017, AIDS.

[22]  Brad T. Sherman,et al.  Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation , 2016, PloS one.

[23]  G. McComsey,et al.  Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy , 2016, Pathogens & immunity.

[24]  M. Lederman,et al.  IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. , 2016, The Journal of clinical investigation.

[25]  A. d’Arminio Monforte,et al.  Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy , 2016, AIDS.

[26]  David J. Volsky,et al.  HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment , 2016, Nature Reviews Neurology.

[27]  MaryPeace McRae.  HIV and viral protein effects on the blood brain barrier , 2016, Tissue barriers.

[28]  Dongyang Huang,et al.  The Role of Circulating Tight Junction Proteins in Evaluating Blood Brain Barrier Disruption following Intracranial Hemorrhage , 2015, Disease markers.

[29]  W. Banks,et al.  Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications , 2015, Brain, Behavior, and Immunity.

[30]  Michael J. Taylor,et al.  Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  M. Lederman,et al.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.

[32]  M. Lederman,et al.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. , 2014, The Journal of infectious diseases.

[33]  V. Sotošek Tokmadžić,et al.  Perforin- and granulysin-mediated cytotoxicity and interleukin 15 play roles in neurocognitive impairment in patients with acute lymphoblastic leukaemia. , 2014, Medical hypotheses.

[34]  Anthony Gamst,et al.  Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline , 2014, Neurology.

[35]  S. Lipshultz,et al.  Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infection. , 2012, Clinical immunology.

[36]  Daocheng Wu,et al.  HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9 , 2012, Brain Research.

[37]  Susan Morgello,et al.  CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy , 2011, AIDS.

[38]  L. Trautmann,et al.  T-cell exhaustion in HIV infection , 2008, Current HIV/AIDS reports.

[39]  J. Becker,et al.  Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.

[40]  Ron D Hays,et al.  Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.1 , 2007, Health and quality of life outcomes.

[41]  P. Oschmann,et al.  Time course of VCAM‐1 and ICAM‐1 in CSF in patients with basal ganglia haemorrhage , 2007, Acta neurologica Scandinavica.

[42]  D. Nixon,et al.  Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. , 2004, The Journal of infectious diseases.

[43]  B. Mégarbane,et al.  Increased diffusion of soluble adhesion molecules in meningitis, severe sepsis and systemic inflammatory response without neurological infection is associated with intrathecal shedding in cases of meningitis , 2004, Intensive Care Medicine.

[44]  C. Achim,et al.  Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. , 1999, The American journal of pathology.

[45]  G. Arendt,et al.  Serum and cerebrospinal fluid levels of soluble intercellular adhesion molecule 1 (sICAM-1) in patients with HIV-1 associated neurological diseases , 1994, Journal of Neuroimmunology.

[46]  Huston Gj,et al.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[47]  S. Sekaran,et al.  Disruption of the blood brain barrier is vital property of neurotropic viral infection of the central nervous system. , 2018, Acta virologica.

[48]  B. Brew,et al.  HIV-associated neurocognitive disorder. , 2018, Handbook of clinical neurology.

[49]  P. Annunziata.  Blood-brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism. , 2003, Journal of neurology.